|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
The biotech company said net income in the fourth quarter totaled $207.7 million, or 70 cents a share, compared with net income of $201 million, or 67 cents a share, a year earlier.
Amylin shares are rising on news that billionaire investor Carl Icahn is building his position in the company.
Botox maker Allergan says fourth-quarter profit fell to $150.6 million, or 50 cents per share, from $160.3 million, or 52 cents per share, in the fourth quarter of 2008.
Travis T. takes umbrage with an article on Sequenom's latest Down syndrome data.
A bid for Wyeth could help Pfizer dominate the Alzheimer's drug market, but doing so carries big risks and challenges.
If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.
Looks like Pfizer's ordering the usual, and if talks to buy fellow drug giant Wyeth pan out, biotech stocks may get burned.
Biogen Idec shares were sliding on concerns that a competitor's oral pill for multiple sclerosis may pinch the company's profits.
Adam Feuerstein gives the lowdown on this year's conference in San Francisco.
Biotech expert Adam Feuerstein explains a sale isn't likely here, regardless of what the company's management says.
Dublin's Elan has hired Citigroup Global Markets to review alternatives, including a minority investment, an alliance, or a merger or sale of the company.
The J.P. Morgan Healthcare Conference kicks off Monday in San Francisco amid troubled times for the biotech sector. Here are some of the top stories to watch for.
Elan and Materials Select SPDR are also seeing options activity.
Biotech expert Adam Feuerstein grades his hits and misses for 2008.
Senior Columnist Adam Feuerstein's selection of Kelly Martin as the worst biotech CEO for 2008 highlights the need for investors to scrutinize management teams before plunging into an investment.
Peter Meldrum Wins Swanson Trophy for pulling off one of the smartest drug licensing deals of all time.
Elan CEO Kelly Martin, Senior Columnist Adam Feuerstein's pick for worst biotech CEO of 2008, is in the crosshairs of a major investor.
A study showed the company's experimental daily pill for multiple sclerosis was more effective than a currently approved injectable drug from Biogen Idec.
Kelly Martin is taking home the Nance Trophy for oustanding achievement in loss of shareholder value, overstated optimism and abject incompetence under pressure.
The biotech has revealed in a regulatory filing a third case of PML, an often deadly infection, in an MS patient taking Tysabri.
The biotech reveals in a regulatory filing a third case of PML, an often deadly infection, in an MS patient taking Tysabri.
Amgen rises on an upheld court ruling regarding two anemia drugs. Mentor shares fall on UBS rating.
Freeport-McMoRan is among the most-searched stocks on TheStreet.com. Here's what Cramer's had to say about it lately.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.